TriangleNCT00911859 · OUTCOME
1-year Survival Rate
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage of participants
- Interval / dispersion
- Not reported
- Time frame
- 1 year
What was measured
Percentage of participants who are alive at the end of year 1 after randomization
Analysis population: Intent-to-treat (ITT) population: all randomized participants
Groups in this outcome
Part 2: VMP (Velcade+Melphalan+Prednisone)
Velcade 1.3 mg/m2 was administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 were taken orally.
Part 2: VMP (Velcade+Melphalan+Prednisone) + Siltuximab
Siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP. VMP: Velcade 1.3 mg/m2 was administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 were taken orally.
| Group | Source count |
|---|---|
| Part 2: VMP (Velcade+Melphalan+Prednisone) | 54 |
| Part 2: VMP (Velcade+Melphalan+Prednisone) + Siltuximab | 52 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 2: VMP (Velcade+Melphalan+Prednisone) | 87.8 | Not reported | Not reported | Not reported | Not reported |
| Part 2: VMP (Velcade+Melphalan+Prednisone) + Siltuximab | 87.5 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 87.8
- group Id
- OG001
- value
- 87.5
- denoms
- counts
- group Id
- OG000
- value
- 54
- group Id
- OG001
- value
- 52
- units
- Participants
- description
- Percentage of participants who are alive at the end of year 1 after randomization
- groups
- description
- Velcade 1.3 mg/m2 was administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 were taken orally.
- id
- OG000
- title
- Part 2: VMP (Velcade+Melphalan+Prednisone)
- description
- Siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP. VMP: Velcade 1.3 mg/m2 was administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 were taken orally.
- id
- OG001
- title
- Part 2: VMP (Velcade+Melphalan+Prednisone) + Siltuximab
- param Type
- NUMBER
- population Description
- Intent-to-treat (ITT) population: all randomized participants
- reporting Status
- POSTED
- time Frame
- 1 year
- title
- 1-year Survival Rate
- type
- SECONDARY
- unit Of Measure
- Percentage of participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice